The present invention relates to a therapeutic preventive agent that
includes an angiogenic factor gene (such as hepatocyte growth factor
(HGF), vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), and hypoxia inducible factor (HIF)) as its active
ingredient, and the administration of such an agent into the targeted
skin diseases-affected area.